Elevation Oncology
New York
About Elevation Oncology
Elevation Oncology makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Its lead candidate, seribantumab, which inhibits tumor growth driven by NRG1 fusions, is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $197.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2023)
- Ticker: nasdaq:ELEV
- Website: elevationoncology.com
- Phone: (716) 371-1125
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/elevation-oncology-84324 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.